$240,000 Grant will allow evaluation of Cetya’s HDAC inhibitors for treatment of sickle cell disease.
Recent Posts
- Cetya Therapeutics welcomes Dr. Anthony Wutoh to its Board of Directors
- Cetya Therapeutics Appoints Ron Lowy to Board of Directors
- Cetya Therapeutics Announces Issuance of New Patents Covering its HDAC Inhibitor CT-102
- Cetya Therapeutics Announces Issuance of New Patent Covering Its Unique Targeted HDAC Inhibitors
- Cetya Therapeutics Announces Phase II STTR Grant Award